中文摘要：

目的观察间质CD10和Ezrin在乳腺导管内癌及浸润性导管癌中的表达，探讨两者在乳腺癌发展中的作用。方法采用免疫组织化学sP法测定60例导管内癌及60例浸润性导管癌中间质CD10和Ezrin的表达。结果间质CD10的表达在浸润性导管癌中为阴性25例、弱阳性18例、强阳性17例，导管内癌中分别为36例、18例、6例，其在浸润性导管癌中的表达水平高于在导管内癌中的表达水平（Z=-2．465，P〈0．05）。Ezrin在导管内癌组的定位为癌细胞腔面15例（30．6％）、胞膜13例（26．5％）、胞质21例（42．9％），在浸润性导管癌组分别为5例（10．2％）、6例（12．2％）、38例（77．6％），其在导管内癌与浸润性导管癌中的细胞内亚定位不同（Х^2=12．477，P〈0．01）。间质CD10的表达水平和Ezrin在癌细胞内的亚定位与无病生存期明显相关（P〈0．05），与肿物分级、大小、ER和PR无明显相关（P〉0．05），与浸润性导管癌中的淋巴结转移无明显相关（P〉0．05）。结论间质CD10表达的增加和Ezrin在癌细胞内亚定位的改变可能促进乳腺导管内癌浸润的发生。

英文摘要：

Objective To evaluate the expression of stromal CD10 and Ezrin in ductal carcinoma in situ （DCIS） and invasive ductal carcinoma （IDC） of breast cancer and examine their role in tumor progression. Methods Immunohistochemistry was used to detect the expression of stromal CD10 and Ezrin in 60 cases of DCIS and 60 cases of IDC. Results In IDC the expression of stromal CD10 was negative in 25 cases, weak in 18 cases, strong in 17 cases, whereas in DCIS the corresponding parts were 36 cases, 18 cases, 6 cases respectively. It was preferentially expressed in IDC compared to DCIS （Z=-2.465, P〈0.05）. In DCIS Ezrin localized at apical was seen in 15 cases （30.6%）, at membrane in 13 cases （26.5%） and in cytoplasm in 21 cases （42.9%）, whereas in IDC the corresponding parts were 5 （10. 2% ） , 6 （12. 2% ）, 38 （77.6% ） respectively. The localization was significantly different between this two groups （Х^2=12. 477, P〈0. 01）. The expression of CD10 and switch of Ezrin localization were positively correlated with disease free survival （P〈0. 05）. There was no correlation between stromal CD10 and tumor grade, tumor size, ER and PR status, and lymph node metastases in IDC. And so did Ezrin. Conclusion The increase in the expression of stromal CD10 and the switch of Ezrin localization might participate in the process of invasion of ductal carcinoma.